Natera (NASDAQ:NTRA) Price Target Raised to $200.00 at JPMorgan Chase & Co.

Natera (NASDAQ:NTRA) had its price target upped by equities research analysts at JPMorgan Chase & Co. from $160.00 to $200.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 15.95% from the company’s current price.

Several other research firms also recently issued reports on NTRA. The Goldman Sachs Group upped their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Craig Hallum increased their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Morgan Stanley upped their price objective on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, Robert W. Baird upped their target price on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $142.94.

Natera Stock Up 3.6 %

NTRA stock opened at $172.49 on Friday. The company has a 50 day moving average of $143.28 and a two-hundred day moving average of $124.06. The company has a market cap of $22.77 billion, a price-to-earnings ratio of -94.57 and a beta of 1.63. Natera has a 12-month low of $57.22 and a 12-month high of $175.63. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.95) earnings per share. On average, equities analysts anticipate that Natera will post -1.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Natera news, Director Rowan E. Chapman sold 1,767 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $170.24, for a total transaction of $300,814.08. Following the transaction, the director now owns 6,202 shares in the company, valued at approximately $1,055,828.48. This represents a 22.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 1,196 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This trade represents a 1.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 137,987 shares of company stock worth $21,895,591 in the last 90 days. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Covestor Ltd grew its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. GAMMA Investing LLC raised its position in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. CIBC Asset Management Inc lifted its stake in Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after acquiring an additional 111 shares during the period. RiverPark Advisors LLC lifted its position in shares of Natera by 3.5% in the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after purchasing an additional 112 shares during the period. Finally, Moss Adams Wealth Advisors LLC lifted its stake in shares of Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.